Clinical Trial Update: Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing osimertinib plus bevacizumab versus osimertinib alone as second-line treatment in metastatic non-small cell lung cancer with EGFR muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• TAGRISSO (osimertinib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Non Small Cell Lung Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2025-01-14